Clinical Trial Update: A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder. [Phase 2]

View source ↗

Summary

A completed Phase 2 safety and effectiveness study of JNJ-31001074 in adults with Attention-Deficit/Hyperactivity Disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• JNJ-31001074

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Attention Deficit Hyperactivity Disorder | Phase 2 | Status: COMPLETED